A multimodal model for clinically defined MCI integrating plasma biomarkers and brain microstructural features: a dual-cohort external validation study

Jia-Yu Ke Saiyare Xuekelati Zhuoya Maimaitiwusiman Buluhan Halan Qi-Hong Xu Shu-Lin Guo Lei Xu Hongmei Wang

Sep 2026 · Neurological Sciences · Vol 47 · 0 citations · 25 references

Medicine

TL;DR

A multimodal signature combining two selected DTI features with three prespecified plasma biomarkers and demographic covariates showed reproducible discrimination of clinically defined MCI across independent cohorts, and support further evaluation of this approach as an adjunctive MCI risk-stratification strategy.

DOI PubMed Semantic Scholar

View source

Similar papers

Aug 2026

Mid-life candidate vascular plasma biomarkers are associated with MRI markers of vascular brain injury and amyloid- and tau-PET in cognitively healthy adults

Background Identifying candidate biomarkers for preclinical dementia could improve our understanding of underlying biological pathways leading to vascular brain injury (VBI) and neurodegeneration. Objective To identify plasma protein markers of MRI markers of VBI and amyloid- and tau-PET burden in cognitively healthy a...

Martin D. Mulligan, Rui-Qi Wang, Qiong Yang et al. · Journal of Alzheimer's Disea... · 0 citations

Sep 2026

Multimodal prediction of MCI-to-dementia conversion over a two-year window.

An explainable multimodal machine-learning framework to predict progression from MCI to dementia within a clinically meaningful two-year period is developed and the convergence of cognitive impairment and region-specific neurodegeneration emerged as the strongest indicator of conversion risk.

Bipul Simkhada, T. Y. Liang, Xue-Ting Cui et al. · GeroScience · 1 citation · ⚡1

Open access Sep 2026

Spatiotemporal Atrophy Subtypes in Alzheimer's Disease: Neurodegenerative-Vascular Associations and Potential Prognostic Value.

Bomarker-confirmed AD comprised internally reproducible atrophy trajectories with distinct cognitive, vascular, and molecular profiles and may complement fluid biomarkers and conventional volumetry for patient stratification and prognosis.

Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al. · NeuroImage · 0 citations

Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · European Radiology Experimen... · 0 citations

Open access Aug 2026

Brain network biomarkers for diagnosis and clinical stratification in multiple sclerosis: a longitudinal study integrating individualised structural covariance MRI with high-density EEG

The iSCN approach identified reliable patterns of topological and connectivity impairment across MS and its clinical stratifications, providing insight into MS neuropathology and guiding future diagnostic and therapeutic biomarker development.

Rui Gao, Xuegang Song, Hanyue Zheng et al. · EBioMedicine · 0 citations

Open access Sep 2026

White Matter Slow-4 fALFF as a Complementary Marker in the Multimodal Alzheimer’s Disease Biomarker Landscape

INTRODUCTION White matter (WM) functional activity, quantified as slow-4 fractional amplitude of low-frequency fluctuations (fALFF; 0.027–0.073 Hz), may reflect Alzheimer’s disease (AD) pathology, but its utility relative to established structural imaging markers remains poorly characterized. METHODS We analyzed 369 AD...

Ya-Li Huang, A. Toga, Lu Zhao · bioRxiv · 0 citations